NCT00262236已完成3 期
A Twelve-week, Randomized, Double-blind, Parallel-group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren Administered Alone and in Combination With Atenolol in Patients With Essential Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 693
- 试验地点
- 2
- 主要终点
- Change from baseline in diastolic blood pressure after 12 weeks
研究概览
简要总结
This is a study for people diagnosed with hypertension to compare the safety and effectiveness of aliskiren alone and in combination with atenolol. Each patient will be in the study for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients 18 years of age and older.
- •Patients with essential hypertension.
排除标准
- •Severe hypertension, Current diagnosis of heart failure, History or evidence of a secondary form of hypertension, Participation in any investigational drug study within one month of planned participation,
- •Other protocol-defined inclusion/exclusion criteria may apply
结局指标
主要结局
Change from baseline in diastolic blood pressure after 12 weeks
次要结局
- Diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 12 weeks
- Blood pressure of < 140/90 mmHg after 12 weeks
- Change from baseline in systolic blood pressure after 12 weeks
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.Essential HypertensionNCT00343551Novartis654
已完成
3 期
Obese Hypertension Study (0954-315)HypertensionNCT00289887Organon and Co261
已完成
4 期
Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic HypertensionStage 2 Systolic HypertensionNCT00931710Novartis488
已完成
3 期
A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)HypertensionNCT00886600Merck Sharp & Dohme LLC122
已完成
2 期
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension PatientsHypertensionNCT00923611Boryung Pharmaceutical Co., Ltd182